22nd Belgian Congress on Rheumatology

26 - 28 September 2018
Centre Culturel, Spa

Final Programme

www.rheumacongress.be
Venues and Map

Centre Culturel de Spa
Rue Servais 8
4900 Spa
http://ccspa-jalhay-stoumont.be/

The Workshops take place at Hotel Radisson Palace, Place Royale 39, located at 300 m from the Centre Culturel de Spa.
Welcome Address

Dear colleagues and friends,

We are very pleased to welcome you to the 22nd Belgian Congress on Rheumatology, taking place in Spa on 26-28 September 2018.

The congress takes place at the Centre Culturel de Spa, located in the very heart of the city of Spa famous for its several natural mineral springs.

We are proud to propose a varied and interesting programme with state-of-the-art keynote lectures and oral communications. The ‘Year in Review’ will also be presented again, providing you with a survey of the Belgian publications of the last year.

Furthermore, a poster tour, 4 workshops for early risers and 11 Updates in Therapeutics are scheduled. The ‘Thieves Market’ is also scheduled again this year.

Together with the KBVR-SRBR Board members, we hope you will enjoy the Congress and the hospitality of Spa!

Yours sincerely,

Vanessa Smith
Scientific Organiser

Catherine Bailleux, Silvana Di Romana, Bernard Lauwerys, Pierre Zangerle
Local Organising Committee
**Wednesday, September 26**

**Young Investigator Meeting**
*Salon Gris*
*Chairs: Thomas Renson (UGent) and Aurélie De Groof (UCL)*

10.00 **Increased susceptibility to develop spontaneous and severe post-traumatic osteoarthritis in DOT1L-deficient mice**
*Astrid de Roover (KUL), Frederique Cornelis, Lies Storms, Ann Hens, Rik Lories, Silvia Monteagudo*

10.15 **Frequency of joint erosions in patients with rheumatoid arthritis, treated with biologics in relation to RF and ACPA serology in real life**
*Lise Heeman (UGent), Philippe Carron, Peggy Jacques*

10.30 **ANP32A regulates ATM expression and prevents oxidative stress in cartilage, brain and bone**
*Frederique Cornelis (KUL), Silvia Monteagudo, Laura-An Guns, Wouter den Hollander, Rob Nelissen, Lies Storms, Tine Peeters, Ilse Jonkers, Ingrid Meulenbelt, Rik Lories*

10.45 **Evaluation of physical performance in patients with axial spondyloarthritis**
*Tomasz Linkowski (ULB), Michel Lamotte, Sophie Bode Blanco, Valérie Gangji, Laure Tant*

11.00 **Psoriasis- and inflammatory bowel disease models co-operate with biomechanical stress in triggering mild joint inflammation**
*Giulia Rossana Gulino, Margot Van Mechelen (KUL), Rik Lories*

11.15 **Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal**
*Maurizio Cutolo, Karin Melsens (UGent), Sara Wijnant, Francesca Ingegnoli, Kristof Thevissen, Filip De Keyser, Saskia Decuman, Ulf Müller-Ladner, Yves Piette, Valeria Riccieri, Nicola Ughi, Els Vandecasteele, Amber Vanhaecke, Vanessa Smith*

11.30 **DOT1L inhibition affects proliferation and the cell cycle of dermal fibroblasts, but has no direct effects on collagen deposition in in vitro and in vivo models of fibrosis**
*Nathalie Berghen (KUL), Ellen De Langhe, Rik Lories*

11.45 **Intensive treatment strategies in low risk patients with early RA: An economic investment**
*Sofia Pazmino (KUL), Rene Westhovens, Johan Joly, Veerle Stouten, Diederick De Cock, Kristien Van der Elst, Patrick Verschueren*

10.30 **Meeting of the BRV-ARB**
*Salon Bleu*

---

**Wednesday, September 26**

12.00 **Welcome Lunch in the Exhibition Hall**

12.30 **Opening Ceremony**
*Vanessa Smith, Scientific Organiser; Bernard Lauwerys and Catherine Bailleux, KBVR-SRBR*

**SESSION 1**
*Main Room*
*Chairs: Marc Léon (CHU Ambroise Paré) and Patrick Verschueren (KUL)*

12.50 **Vesalius Lecture**
*Clinically suspect arthralgia*
*Annette van der Helm (Leiden, The Netherlands)*

**Abstract Presentations**

13.35 **High need for anti-TNF therapy after withdrawal strategy in early peripheral Spondyloarthritis**
*Philippe Carron (UGent), Gaëlle Varkas, Thomas Renson, Anne-Sophie De Craemer, Dirk Elewaut, Filip Van den Bosch*

13.45 **Correlation between different evaluation scores in RA patients treated with tocilizumab; Data from the PATHOS trial**
*Luc De Clerck (UZA), Julie Piessevaux, Steven De Sitter*

13.55 **MMP7 and CXCL12: Two promising biomarkers in lupus nephritis**
* Sylvie Goletti (UCL), Sèverine Nieuwland-Husson, Anne-Lise Maudoux, Frédéric Houssiau, Bernard Lauwerys*

14.05 **FWRO/FRSR Award Ceremony**
*Chairs: René Westhovens (KUL) and Philippe Carron (UGent)*

14.30 **Update in Therapeutics – Organised with an educational grant from Sanofi**
*What's new in the management of RA?*
*Cem Gabay (Geneva, Switzerland)*

15.00 **Update in Therapeutics – Organised with an educational grant from Pfizer**
*Imaging in psoriatic arthritis*
*Mikkel Ostergaard (Glostrup, Denmark)*

15.30 **Coffee Break in the Exhibition Hall**
**Thursday, September 27**

**Workshop 1**

Room Terra 1

08.00

Chairs: Joris De Kock (ASZ Aalst) and Laurent Méric de Bellefon (UCL, CNDG & CHU St. Pierre)

*Intra-articular injections and biopsy under ultrasound guidance*

Anne Durnez (AZ Jan Portaels Vilvoorde, UCL), Alla Ishchenko (ZNA Jan Palfijn, Middelheim hospital, UZ Gasthuisberg, KUL), Maria-José Fernandez (Centre Medicis, UZ Antwerpen), Laurent Méric de Bellefon (CNDG, CHU Saint-Pierre Brussels, UCL), Adrien Nzeusseu Toukap (UCL), Ruth Wittoek (UGent & ZNA Jan Palfijn), Maria S. Stoenoiu (UCL)

**Workshop 2**

Room Terra 2

Chairs: Nancy Van Den Bossche (AZ Nikolaas) and Marie Vanthuyne (UCL)

*How to evaluate muscle strength*

Yves Piette (AZ Sint-Jan & UGent)

---

**SESSION 4**

Main Room

Chair: Valérie Badot (CHU Brugmann) and Frédéric Houssiau (UCL)

**Abstract Presentations**

09.00

*Longitudinal evaluation of lung disease progression in mouse models of metastasis, inflammation and fibrosis: Radiosafety of low-dose high-resolution micro-CT protocols*

Nathalie Berghen (KUL), Kaat Dekoster, Eyra Mariën, Amy Hillen, Jens Wouters, Jasmine Defermes, Thibault Vosselman, Eline Tiest, Ria Bogaerts, Marleen Lox, Ellen De Langhe, Marc Hoylaerts, Rik Lories, Greetje Vande Velde

09.10

*Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases*

Maurizio Cutole, Karin Melsens, Ariane L. Herrick, Ivan Foeldvari, Ellen Deschepper, Filip De Keyser, Oliver Distler, Francesca Ingegnoli, Yora Mostmans, Ulf Müller-Ladner, Carmen Pizzorni, Valeria Riccioti, Barbara Ruaro, Alberto Sulli, Amelia C. Trombetta, Amber Vanhaecke (UGent), Vanessa Smith
Thursday, September 27

09.20  Comparison between the Disease Activity Score and the Revised EUSTAR Activity Index in diffuse cutaneous systemic sclerosis (dcSSc) patients

  Marie Doyen (UCL), Frédéric Houssiau, Bernard Lauwerys, Marie Vanthuyne

09.30  Stem cell transplantation in Rheumatology: Friend or foe?

  Jaap van Laar (Utrecht, The Netherlands)

10.15  Year in review – Clinical and basic science

  Philippe Carron (UGent and AZ Alma) and Peggy Jacques (UGent)

10.45  Coffee Break in the Exhibition Hall

SESSION 5  Main Room

  Chairs: Béatrice André (CHU de Liège) and Mark Walschot (VUB)

11.15  Update in Therapeutics – Organised with an educational grant from Eli Lilly

  Unlocking the potential of real world evidence in fighting rheumatoid arthritis

  Brieuc van Damme, former political advisor and guest lecturer at universities of Ghent and Antwerp; founder of policy consultancy company Baere Craft

11.45  Update in Therapeutics – Organised with an educational grant from BMS

  Immunology: What’s in it for me and patients?

  Pierre Coulie (UCL)

12.15  Intersitial lung disease in connective tissue diseases

  Wim Wuyts (KUL)

12.45  Lunch in the Exhibition Hall

13.30  Poster Tour in the Exhibition Hall

  Tour Leader: Ellen De Langhe (KUL)

14.00  General Assembly - Part II  Main Room

Thursday, September 27

SESSION 6  Main Room

  Chairs: Philip Remans (Reumacentrum Genk) and Joke Dehoorne (UGent)

14.15  Update in Therapeutics – Organised with an educational grant from MSD

  Checkpoint inhibitors

  Sandrine Aspeslagh (Bordet)

14.45  Update in Therapeutics – Organised with an educational grant from Novartis

  Targeting remission in axial spondyloarthritis

  Kurt de Vlam (KUL)

15.15  All we need to know about juveniles

  Nicola Ruperto (Genova, Italy)

15.50  Coffee Break in the Exhibition Hall

SESSION 7  Main Room

  Chairs: Bouchra Lechkar (H.-Hartziekenhuis Lier) and Silvano Dell’Armellina (CNDG)

  Abstract Presentations

16.20  Is calprotectin a useful diagnostic tool in diagnosing spondyloarthropathies?

  Lieve Van Hoovels (OLV Aalst), Stefanie Van Den Bremt, Toon Schiemsky, Mathieu Cauchie, Bert Vander Cruyssen, Xavier Bossuyt, Muriel Stubbe

16.30  Mechanical strain determines the site-specific direction of inflammation and tissue damage in arthritis

  Isabelle Cambre (UGent), Djoere Gaublomme, Arne Burssens, Peggy Jacques, Nadia Schryvers, Amelie De Munck, Leander Meuris, Stijn Lambrecht, Shea Carter, Luc Van Hoorebeke, George Kollia, Nico Callewaert, Rik Lories, Georg Schett, Dirk Elewaut

16.40  GPR22 signaling contributes to osteoarthritis in mice by stimulating chondrocyte hypertrophy

  Laura-An Guns (KUL), Silvia Monteagudo, Davide Calebiro, Chris Esapa, Andrew Nesbit, Roger Cox, Steve Brown, Rajesh Thakker, Martin Lohse, Frédéric Cailotto, Rik Lories

16.50  Update in Therapeutics – Organised with an educational grant from Celgene

  Adressing comorbidities in psoriatic arthritis

  Frank Behrens (Frankfurt am Main, Germany)

17.20  End of Day 2
Friday, September 28

08.00 Workshop 3  Room Terra 1
Chairs: Caroline Verbist (AZ Sint-Lucas) and Muhammad Soyfoo (ULB)

Skin in rheumatology: Cases and clinical images
Petra De Hoes (KUL)

Workshop 4  Room Terra 2
Chairs: Olivier Malaise (CHU de Liège) and Jan Lenaerts (KUL & Reuma-Instituut Hasselt)

Imaging in hand osteoarthritis
Ruth Wittoek (UGent & ZNA Jan Palfijn)

The Workshops take place at Hotel Radisson Palace, Place Royale 39 (located at 300 m from the Centre Culturel de Spa)

SESSION 8  Main Room
Chairs: Ruth Wittoek (UGent & ZNA Jan Palfijn) and Louis Van Praet (AZ Sint-Jan)

09.00 Difficult clinical cases in osteoporosis
Hans Zmierczak (UGent)

Abstract Presentations

09.30 Identification of joint locations that are poor prognostic and require more intensive therapy in an early, rapidly progressing RA cohort: A post hoc agree analysis
Patrick Durez (UCL), Sofie Robert, Alexandra Thiry, Harris Ahmad

09.40 Effectiveness of a randomized step-down to methotrexate or leflunomide maintenance therapy in patients with low disease activity, 40 weeks after starting combined methotrexate-leflunomide remission induction therapy in early rheumatoid arthritis: Results from the CareRA trial
Veerle Stouten (KUL), Steven Michiels, Amy Belba, Rene Westhovens, Patrick Verschueren

09.50 Rheumatic diseases in rheumatology practices: Comparison with a historical cohort and evaluation of disease activity application
Hubert Berghs, Marleen Coppens, Isabelle De Wergifosse, Iona Gofita, Spyridon Kefalas, Christine Langenaken, Jan Lenaerts, Philip Remans, Anne Sileghem, Johan Vanhoof, Kristel Van Landuyt, Paul Van Wanghe, Pascale Volders, Piet Geusens (LOK Reumatologen Limburg)

SESSION 9  Main Room
Chairs: Anne Durnez (AZ Jan Portaels, UCL) and Valérie Lambrecht (Maria Middelares)

Thieves Market

12.00 Periarticular and vascular calcifications in a young woman due to CD73 deficiency
Steven Van Offel (UZA), Silke Peeters, Geert Mortier, Luc De Clerck, Jan Van Offel

12.10 Treating vasculitis with Tocilizumab: Beware of deception by CRP!
Stephanie Detailleur (KUL), Jan Lenaerts, Ellen De Langhe, Rene Westhovens, Patrick Verschueren

12.20 Nivolumab as a possible trigger for pseudo-gout: A case report
Isabel Clinck (UZA), Jan Van Offel, Luc De Clerck, Annelies Janssens, Jan Van Meerbeeck

12.30 Closure of the Congress
Vanessa Smith, Scientific Organiser

12.45 Farewell Lunch in the Exhibition Hall

13.30 KBVR-SRBR Board Meeting at Hotel Radisson Palace  Room Terra 1
Thursday, September 27

Meeting for Health Professionals in Rheumatology - Morning
Organised by the Belgian Health Professionals in Rheumatology (BHPR) vzw/asbl
Chairpersons: Karlien Claes (UZ Ghent) and Thijs Swinnen (KU Leuven)

08.45 Registration*

09.00 Welcome to the Health Professionals in Rheumatology Meeting
Karlien Claes, Rheumatology Nurse; Rheumatology, Ghent University Hospital; Member of the BeHPR vzw/asbl
Thijs Swinnen, Physiotherapist, University Hospitals Leuven; Researcher, Skeletal Biology and Engineering Research Center, KU Leuven; chair of the BHPR vzw/asbl

09.10 Clinical research in the UK: from pen and paper to a fitbit
Diederik De Cock, Post-doctoral research associate, Centre for Epidemiology, Centre for Musculoskeletal Research, University of Manchester

09.40 Patient perspectives and outcomes over time: Lessons for clinical practice
Kristien Van der Elst, Nurse, University Hospitals Leuven; PhD, Department of Public Health and Primary Care, KU Leuven; Skeletal Biology and Engineering Research Center, KU Leuven

10.00 Coffee Break in Salon Bleu

10.20 ReumaWerkt: Project overview
Anja Marchal, Social worker, Return to Work Coordinator, ReumaNet vzw
Saskia Decuman, Occupational therapist, expert research and development, National Institute of Health and Disability Insurance (RIZIV)

10.35 ReumaWerkt: Practical workshop
Anja Marchal, Social worker, Return to Work Coordinator, ReumaNet vzw
Saskia Decuman, Occupational therapist, expert research and development, National Institute of Health and Disability Insurance (RIZIV)

11.00 Nutrition and fat: New venues
Ruth Wittoek, Rheumatologist, Department of Rheumatology, University Hospital Ghent & ZNA Jan Palfijn

11.30 Targeted and biological DMARDs: Do we need a yearly update?
Heleen Cyppers, Rheumatology resident, Department of Rheumatology, Ghent University Hospital; VIB Center for Inflammation Research, Ghent University

12.00 Lunch and Networking in Salon Bleu

Thursday, September 27

Meeting for Health Professionals in Rheumatology - Afternoon
Organised by the Belgian Health Professionals in Rheumatology (BHPR) vzw/asbl
Chairpersons: Karlien Claes (UZ Ghent) and Thijs Swinnen (KU Leuven)

13.00 General Assembly Belgian Health Professionals in Rheumatology vzw/asbl
(welcome - and a must do - to all)

13.15 New board elections and discussion on focus for 2019 and working groups

13.45 Short Break for Dessert in Salon Bleu

14.00 What’s hot in Rheumatology? Part II
EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis: an update
Yvonne Van Eijk-Hustings, Nurse, department of patient and care, clinical epidemiology and medical technology assessment, Maastricht University Medical Centre; School CAPHRI, Care and Public Health Research Institute, Maastricht University

14.45 Coffee Break in Salon Bleu

15.00 Workshop
Virtual reality in the management of pain, stress and anxiety: useful for rheumatology?
Diane Jooris, MS, CEO & Co-founder Oncomfort company

16.00 Closing
Past and new chair BHPR

*Registration includes coffee breaks and lunch.
General Information

Venues
Centre Culturel de Spa
Rue Servais 8
4900 Spa
http://ccspa-jalhay-stoumont.be/

The Workshops take place in rooms Terra 1 & 2 (1st floor) at Hotel Radisson Palace, Place Royale 39 (located at 300 m from the Centre Culturel de Spa). See map on page 2.

Poster Presentations
The poster dimensions are:
max width: 90 cm
max height: 120-150 cm (= PORTRAIT position)

Installation:
Wednesday, September 26 between 12.00 and 20.00 hrs or
Thursday, September 27 between 08.00 and 10.30 hrs

Removal:
Friday, September 28 between 12.30 and 13.00 hrs

Tape will be available at the registration desk.

Accreditation
A request for accreditation has been submitted to the RIZIV/INAMI. A certificate of attendance will be sent by email after the Congress.
Please make sure to sign the attendance list each day at the KBVR-SRBR booth.

Exhibition
A medical exhibition will be held on the occasion of the Congress. Access is free for registered participants. The exhibition is not accessible for non-MDs.

Liability
Neither the organisers nor Medicongress accept liability for damages and/or losses of any kind which may be incurred by Congress participants during the Congress. Participants are advised to take out insurance against loss, accidents or damage which could be incurred during the Congress.

Bus Transport

Bus transport between Hotels Silva and Balmoral and the Centre Culturel de Spa
Free bus transport is offered to the BCR’18 participants and exhibitors staying at Hotel Silva and at Hotel Balmoral on the following days and times:

Wednesday, September 26
From Silva to the Centre Culturel: 09.00 – 10.00 – 11.00 – 12.00 hrs
From Balmoral to the Centre Culturel: 09.05 – 10.05 – 11.05 – 12.05 hrs
From the Centre Culturel to Silva & Balmoral: 22.00 hrs
From Hotel Radisson Palace (Get-together) to Silva & Balmoral: 22.30 – 23.00 – 23.30 – 24.00 hrs

Thursday, September 27
From Silva to Hotel Radisson Palace (Workshops): 07.30 hrs
From Balmoral to Hotel Radisson Palace (Workshops): 07.35 hrs
From Silva & Balmoral to the Centre Culturel: 08.30 hrs
From the Centre Culturel to Silva & Balmoral: 17.20 hrs

Friday, September 28
From Silva to Hotel Radisson Palace (Workshops): 07.30 hrs
From Balmoral to Hotel Radisson Palace (Workshops): 07.35 hrs
From Silva & Balmoral to the Centre Culturel: 08.30 hrs
From the Centre Culturel to Silva & Balmoral: 13.30 hrs
Registration

| Registration Fees | LATE  
|-------------------|------
| As of 1 September  |
| Members KBVR-SRBR  | € 250,00 |
| Non Members       | € 350,00 |
| Trainees in Rheumatology* | € 75,00 |
| Other Trainees*   | € 100,00 |
| Researchers non-MD* | € 75,00 |
| Emeriti           | € 75,00 |

Workshops** Free
Health Professionals Meeting Free

* Registration as a trainee or researcher non-MD will only be accepted if accompanied by your student card or a certificate of your director. Without proof the non-member fee will be charged.

** Participation in the workshops is free of charge and is limited to 20 participants.

The registration fee for participants includes
- Participation in all scientific sessions
- Participation in the hands-on workshops (separate registration required, limited to 20 participants)
- Participation in the ‘Updates in Therapeutics’ organised by the Industry
- Congress bag with the Programme and Abstracts, tourist info and congress related documents
- Access to the exhibition
- Lunches and coffee breaks

Cancellations
Participants canceling their registration before 1 September 2018, will receive a full refund, less € 50,00 administration costs. There will be no refunds for cancellations received after this date. Cancellations must be confirmed in writing to the Organising Secretariat. All refunds will be processed after the Congress.

Notes
The Organising Committee of the 22nd Belgian Congress on Rheumatology would like to thank

**Major Sponsors**
- AbbVie
- Amgen
- Biogen Belgium
- Bristol-Myers Squibb
- Celgene
- Eli Lilly
- MSD Belgium
- Novartis Pharma
- Pfizer
- Roche
- Sanofi Genzyme

**Exhibitors**
- Analogic Benelux
- GE Healthcare
- Benetec
- Esaote Europe
- Grünewald
- Hemics
- Lamepro
- Sandoz
- Tiiman
- TRB Cheomedica
- UCB Pharma
**Right on target!**

**Fast road to a better future for your patients with spondyloarthritis!**

---

**Cosentyx® secukinumab**

- **Mode of delivery:** Medicinal product subject to medical prescription. **Marketing authorisation holder and numbers:** Novartis Europharm Limited, Frimley Business Park, Camberley GU16 7SR, United Kingdom; EU/1/14/980/001- EU/1/14/980/007

---

**Contraindications:** Severe hypersensitivity reactions to the active substance or to any of the excipients. Clinically important, active infection (e.g. active tuberculosis). **Undesirable effects:** Summary of the safety profile: see full leaflet. List of adverse reactions: ADRs from psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies as well as from post-marketing experience (Table 1) are listed by MedDRA system organ class. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data).

| Name: Cosentyx 150 mg solution for injection in pre-filled syringe / Cosentyx 150 mg solution for injection in pre-filled pen Composition: Each pre-filled syringe contains 150 mg secukinumab* in 1 ml / Each pre-filled pen contains 150 mg secukinumab* in 1 ml. * Secukinumab is a recombinant fully human monoclonal antibody selective for interleukin-17A. Secukinumab is of the IgG1x-class produced in Chinese Hamster Ovary (CHO) cells. For the full list of excipients, see full leaflet. Pharmaceutical form: Solution for injection in pre-filled syringe (injection). The solution is clear and colourless to slightly yellow / Solution for injection in pre-filled pen (Sensoready® pen). The solution is clear and colourless to slightly yellow. Therapeutic indications: Plaque psoriasis: Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis: Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Ankylosing spondylitis: Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Posology: Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Plaque psoriasis. The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Psoriatic arthritis. For patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders (IR), the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300 mg dose is given as two subcutaneous injections of 150 mg. For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Ankylosing spondylitis. The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Each 300 mg dose is given as two subcutaneous injections of 150 mg. For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Renal impairment / hepatic impairment: Cosentyx has not been studied in these patient populations. No dose recommendations can be made. Paediatric population: The efficacy and safety of Cosentyx in children below the age of 18 years have not yet been established. No data are available.**

---

**Summary of the safety profile:** see full leaflet. **List of adverse reactions:** ADRs from psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies as well as from post-marketing experience (Table 1) are listed by MedDRA system organ class. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available data). List of adverse reactions in clinical studies and post-marketing experience: Infections and infestations: Very common: Upper respiratory tract infections; Common: Oral herpes; Uncommon: Oral candidiasis; Uncommon: Tinea pedis; Uncommon: Otitis externa. Not known: Mucosal and cutaneous candidiasis (including oesophageal candidiasis). Blood and lymphatic system disorders: Uncommon: Neutropenia. Immune system disorder: Rare: Anaphylactic reactions. Eye disorders: Uncommon: Conjunctivitis. Respiratory, thoracic and mediastinal disorders: Common: Rhinorrhea. Gastrointestinal disorders: Common: Diarrhoea. Skin and subcutaneous tissue disorders: Uncommon: Urticaria. Placebo-controlled clinical studies (phase III) in plaque psoriasis, PsA and AS patients exposed to 300 mg, 150 mg or placebo up to 12 weeks (psoriasis) or 16 weeks (PsA and AS) treatment duration. Description of selected adverse reactions: Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. **Mode of delivery:** Medicinal product subject to medical prescription. **Marketing authorisation holder and numbers:** Novartis Europharm Limited, Frimley Business Park, Camberley GU16 7SR, United Kingdom; EU/1/14/980/001- EU/1/14/980/007

---

**Date of revision of the text:** 15.08.2017

---

**Co-payment**

<table>
<thead>
<tr>
<th>Name</th>
<th>P.P.</th>
<th>Co-payment*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cosentyx® 2x150 mg</td>
<td>€ 1.119,46</td>
<td>€ 11,90</td>
</tr>
<tr>
<td>Cosentyx® 1x150 mg</td>
<td>€ 564,27</td>
<td>€ 11,90</td>
</tr>
</tbody>
</table>

---

* ordinary insured persons (preferentially insured persons €7.50) - 1. Cosentyx® SmPC